Advisors Asset Management Inc. raised its holdings in Simulations Plus, Inc. (NASDAQ:SLP) by 284.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 711 shares of the technology company’s stock after buying an additional 526 shares during the period. Advisors Asset Management Inc.’s holdings in Simulations Plus were worth $45,000 as of its most recent SEC filing.
A number of other institutional investors have also bought and sold shares of SLP. OLD Mission Capital LLC acquired a new stake in Simulations Plus in the third quarter valued at $309,000. Comerica Bank increased its position in shares of Simulations Plus by 96.7% during the fourth quarter. Comerica Bank now owns 30,007 shares of the technology company’s stock worth $2,239,000 after purchasing an additional 14,748 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Simulations Plus by 20.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,356 shares of the technology company’s stock worth $169,000 after purchasing an additional 400 shares in the last quarter. First Trust Advisors LP acquired a new stake in shares of Simulations Plus during the fourth quarter worth about $2,790,000. Finally, Los Angeles Capital Management LLC increased its position in shares of Simulations Plus by 111.1% during the fourth quarter. Los Angeles Capital Management LLC now owns 5,768 shares of the technology company’s stock worth $415,000 after purchasing an additional 3,035 shares in the last quarter. Institutional investors own 66.42% of the company’s stock.
Shares of SLP stock opened at $53.65 on Friday. Simulations Plus, Inc. has a fifty-two week low of $47.36 and a fifty-two week high of $90.92. The stock has a market capitalization of $1.08 billion, a PE ratio of 99.35, a P/E/G ratio of 6.36 and a beta of -0.09. The firm has a fifty day moving average price of $58.04.
The business also recently disclosed a quarterly dividend, which was paid on Monday, May 3rd. Investors of record on Monday, April 26th were given a dividend of $0.06 per share. This represents a $0.24 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date was Friday, April 23rd. Simulations Plus’s dividend payout ratio is presently 42.86%.
In related news, Director Walter S. Woltosz sold 24,000 shares of Simulations Plus stock in a transaction dated Monday, April 26th. The stock was sold at an average price of $68.54, for a total transaction of $1,644,960.00. Following the completion of the sale, the director now owns 4,519,478 shares in the company, valued at approximately $309,765,022.12. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Walter S. Woltosz sold 13,825 shares of Simulations Plus stock in a transaction dated Monday, May 24th. The stock was sold at an average price of $52.18, for a total value of $721,388.50. Following the sale, the director now owns 4,494,071 shares of the company’s stock, valued at approximately $234,500,624.78. The disclosure for this sale can be found here. In the last quarter, insiders have sold 61,825 shares of company stock valued at $3,807,309. 23.24% of the stock is currently owned by company insiders.
A number of equities analysts recently issued reports on SLP shares. Zacks Investment Research lowered Simulations Plus from a “hold” rating to a “sell” rating in a report on Friday, April 16th. Craig Hallum reduced their target price on Simulations Plus from $81.00 to $74.00 and set a “hold” rating for the company in a report on Tuesday, April 13th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $80.20.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments.
Read More: What are convertible shares?
Want to see what other hedge funds are holding SLP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Simulations Plus, Inc. (NASDAQ:SLP).
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.